ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis

Clinica Chimica Acta

Volumn 445, Issue , 2015, Pages 79-84

  Naito, Takafumi ^a   Mino, Yasuaki ^a   Aoki, Yuki ^a,b   Hirano, Kumi ^a   Shimoyama, Kumiko ^a   Ogawa, Noriyoshi ^a   Kagawa, Yoshiyuki ^b   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

ABCB1; CYP3A5; Genetic variant; Renal function; Rheumatoid arthritis; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CYP3A5 GENE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ALLELE; ARTHRITIS, RHEUMATOID; BIOTRANSFORMATION; BLOOD; DRUG EFFECTS; DRUG MONITORING; GENE FREQUENCY; GENETICS; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ALLELES; ARTHRITIS, RHEUMATOID; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DRUG MONITORING; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84925936227     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.03.021     Document Type: Article

References (34)

1. Lundy S.K., Sarkar S., Tesmer L.A., Fox D.A. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther 2007, 9:202.
2. Fleischmann R., Iqbal I., Stern R.L. Tacrolimus in rheumatoid arthritis. Expert Opin Pharmacother 2006, 7:91-98.
3. Kremer J.M., Habros J.S., Kolba K.S., et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum 2003, 48:2763-2768.
4. Yocum D.E., Furst D.E., Kaine J.L., et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 2003, 48:3328-3337.
5. Böttiger Y., Brattström C., Tydén G., Säwe J., Groth C.G. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999, 48:445-448.
6. Gonschior A.K., Christians U., Winkler M., Linck A., Baumann J., Sewing K.F. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 1996, 42:1426-1432.
7. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
8. Hesselink D.A., Van Schaik R.H., Van der Heiden I.P., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003, 74:245-254.
9. Haufroid V., Mourad M., Van Kerckhove V., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004, 14:147-154.
10. Haufroid V., Wallemacq P., Van Kerckhove V., et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006, 6:2706-2713.
11. Zheng H., Webber S., Zeevi A., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003, 3:477-483.
12. Macphee I.A., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002, 74:1486-1489.
13. Hirano K., Naito T., Mino Y., Takayama T., Ozono S., Kawakami J. Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients. Clin Chim Acta 2012, 414:120-124.
14. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993, 268:6077-6080.
15. Kimchi-Sarfaty C., Oh J.M., Kim I.W., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 26(315):525-528.
16. Mai I., Perloff E.S., Bauer S., et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004, 58:548-553.
17. Kondo H., Abe T., Hashimoto H., et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004, 31:243-251.
18. Furst D.E., Saag K., Fleischmann M.R., et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002, 46:2020-2028.
19. Morita Y., Sasae Y., Sakuta T., Satoh M., Sasaki T., Kashihara N. Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol 2008, 18:379-384.
20. Hirano K., Maruyama S., Mino Y., Naito T., Kawakami J. Suitability of chemiluminescent enzyme immunoassay for the measurement of blood tacrolimus concentrations in rheumatoid arthritis. Clin Biochem 2011, 44:397-402.
21. Fukuen S., Fukuda T., Maune H., et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002, 12:331-334.
22. Park H.J., Shinn H.K., Ryu S.H., Lee H.S., Park C.S., Kang J.H. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007, 81:539-546.
23. Kamdem L.K., Streit F., Zanger U.M., et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005, 51:1374-1381.
24. Lamba J., Strom S., Venkataramanan R., et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006, 79:325-338.
25. Hosohata K., Masuda S., Yonezawa A., et al. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm Res 2009, 26:1590-1595.
26. Tsujimura S., Saito K., Nawata M., Nakayamada S., Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2008, 67:380-388.
27. Olyaei A.J., De Mattos A.M., Bennett W.M. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf 1999, 21:471-488.
28. Gijsen V.M., Madadi P., Dube M.P., Hesselink D.A., Koren G., De Wildt S.N. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant 2012, 17:111-121.
29. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575.
30. Kuypers D.R., De Jonge H., Naesens M., Lerut E., Verbeke K., Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007, 82:711-725.
31. Fukudo M., Yano I., Yoshimura A., et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008, 18:413-423.
32. Naesens M., Lerut E., De Jonge H., Van Damme B., Vanrenterghem Y., Kuypers D.R. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009, 20:2468-2480.
33. Hebert M.F., Dowling A.L., Gierwatowski C., et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003, 13:661-674.
34. Hawwa A.F., McKiernan P.J., Shields M., Millership J.S., Collier P.S., McElnay J.C. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009, 68:413-421.